These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35689489)

  • 1. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.
    Pratta M; Paczesny S; Socie G; Barkey N; Liu H; Owens S; Arbushites MC; Schroeder MA; Howell MD
    Br J Haematol; 2022 Aug; 198(4):729-739. PubMed ID: 35689489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
    Zeiser R; Socié G; Schroeder MA; Abhyankar S; Vaz CP; Kwon M; Clausen J; Volodin L; Giebel S; Chacon MJ; Meyers G; Ghosh M; Deeren D; Sanz J; Morariu-Zamfir R; Arbushites M; Lakshminarayanan M; Barbour AM; Chen YB
    Lancet Haematol; 2022 Jan; 9(1):e14-e25. PubMed ID: 34971577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
    Etra A; Capellini A; Alousi A; Al Malki MM; Choe H; DeFilipp Z; Hogan WJ; Kitko CL; Ayuk F; Baez J; Gandhi I; Kasikis S; Gleich S; Hexner E; Hoepting M; Kapoor U; Kowalyk S; Kwon D; Langston A; Mielcarek M; Morales G; Özbek U; Qayed M; Reshef R; Rösler W; Spyrou N; Young R; Chen YB; Ferrara JLM; Levine JE
    Blood; 2023 Feb; 141(5):481-489. PubMed ID: 36095841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
    Schroeder MA; Khoury HJ; Jagasia M; Ali H; Schiller GJ; Staser K; Choi J; Gehrs L; Arbushites MC; Yan Y; Langmuir P; Srinivas N; Pratta M; Perales MA; Chen YB; Meyers G; DiPersio JF
    Blood Adv; 2020 Apr; 4(8):1656-1669. PubMed ID: 32324888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
    Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
    Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Itacitinib Population Pharmacokinetics and Exposure-Response in Patients With Acute Graft-Versus-Host Disease.
    Chen X; Xun Z; Yuska B; McGee R; Yeleswaram S
    J Clin Pharmacol; 2023 May; 63(5):622-632. PubMed ID: 36601737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
    Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Itacitinib prevents xenogeneic GVHD in humanized mice.
    Courtois J; Ritacco C; Dubois S; Canti L; Vandenhove B; Seidel L; Daulne C; Caers J; Servais S; Beguin Y; Ehx G; Baron F
    Bone Marrow Transplant; 2021 Nov; 56(11):2672-2681. PubMed ID: 34172892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
    Srinivas N; Barbour AM; Epstein N; Zhou G; Petusky S; Xun Z; Yuska B; Marbury T; Chen X; Yeleswaram S; Punwani N
    J Clin Pharmacol; 2020 Aug; 60(8):1022-1029. PubMed ID: 32149388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
    Zeidan AM; Cook RJ; Bordoni R; Berenson JR; Edenfield WJ; Mohan S; Zhou G; Asatiani E; Srinivas N; Savona MR
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):523-534. PubMed ID: 35260349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
    Covington M; He X; Scuron M; Li J; Collins R; Juvekar A; Shin N; Favata M; Gallagher K; Sarah S; Xue CB; Peel M; Burke K; Oliver J; Fay B; Yao W; Huang T; Scherle P; Diamond S; Newton R; Zhang Y; Smith P
    Eur J Pharmacol; 2020 Oct; 885():173505. PubMed ID: 32861662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
    Barbour AM; Rockich K; Cimino E; Zhou G; Leonetti-Whalen C; Chen X; Yeleswaram S; Epstein N; Punwani N
    J Clin Pharmacol; 2021 Jul; 61(7):954-960. PubMed ID: 33434286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
    Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
    Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
    Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
    Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
    Abedin SM; Hamadani M
    Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Murata M; Nakasone H; Kanda J; Nakane T; Furukawa T; Fukuda T; Mori T; Taniguchi S; Eto T; Ohashi K; Hino M; Inoue M; Ogawa H; Atsuta Y; Nagamura-Inoue T; Yabe H; Morishima Y; Sakamaki H; Suzuki R
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1183-9. PubMed ID: 23676716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
    Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R
    Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
    Al Malki MM; London K; Baez J; Akahoshi Y; Hogan WJ; Etra A; Choe H; Hexner E; Langston A; Abhyankar S; Ponce DM; DeFilipp Z; Kitko CL; Adekola K; Reshef R; Ayuk F; Capellini A; Chanswangphuwana C; Eder M; Eng G; Gandhi I; Grupp S; Gleich S; Holler E; Javorniczky NR; Kasikis S; Kowalyk S; Morales G; Özbek U; Rösler W; Spyrou N; Yanik G; Young R; Chen YB; Nakamura R; Ferrara JLM; Levine JE
    Blood Adv; 2023 Sep; 7(17):5189-5198. PubMed ID: 37235690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
    Presland RB
    Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.